Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

ArtPlac Artificial Placenta (ArtPlac) - Miniaturized Integrated Lung and Kidney Support for Critically Ill Newborns

Coordinator
Klinikum Nurnberg, Germany
Runs
1 April 2023 to 31 March 2027
Status
Running
EU funding
€4.2m
Total cost
€4.2m
Partners
11 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101099596

What the project is doing

In the project's own words, from its summary on CORDIS.

This Pathfinder project will establish a radical change in the treatment of newborns using an artificial placenta (ArtPlac). What drives us towards a radical new treatment approach? 2 mio. neonatal deaths that occur worldwide yearly. The technological advancements of the last fifty years were based on scaling down adult devices which are not ideal for all babies. Why? Because babies are not just small adults! In fact, the applied treatments are very invasive and cause side effects by damaging their sensitive bodies.

Survivors often suffer from life-long complications or cannot live independently. In utero, the placenta is a life-giving organ and serves as fetal lung, fetal kidney, and feeder. Because the placenta cannot be reconnected after preterm birth, we aim to continue the placental support with ArtPlac. Our novel device simply connects to the belly button for lung and kidney support while the newborn can breathe, mature, and heal.

To achieve this, a novel compact and miniaturized all-in-one artificial placenta device combining lung and kidney functions will be developed. Our plug-in approach will use the natural umbilical vessels at the belly button with expandable catheters to provide a large bore vascular access like in utero. This allows ArtPlac to be driven solely by the newborn's heart like in the womb. Inline sensors will analyze blood parameters without painful collection.

Feedback loops in ArtPlac will provide individual demand-driven support. Inbuilt features for hemocompatibility will prevent thrombosis and use of high-dose systemic anticoagulation with the high risk for brain bleeding. Importantly, ArtPlac allows family integrated care providing a therapy for the newborn in close connection to its family. In summary, our visionary approach revolutionizes the treatment of newborns after birth.

It will reduce brain damage and comorbidities, promote long-term health, and therefore improve the survival chances of up to 1.2 mio. newborns per year.

Topics

Who is involved

OrganisationCityCountryRole
Klinikum NurnbergNurnbergGermanyCoordinator
Mcmaster UniversityHamiltonCanadaAssociatedpartner
Deutsches Herzzentrum MunchenMunichGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Global Foundation for the Care of Newborn InfantsMunchenGermanyParticipant
Maquet Cardiopulmonary GmbHRastattGermanyParticipant
Arrotek Medical LimitedSligoIrelandParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Universiteit TwenteEnschedeNetherlandsParticipant
Universidade Do MinhoBragaPortugalParticipant
Kungliga Tekniska HoegskolanStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI